37,155 XNAS Volume
XNAS 25 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Diego Miralles | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 3,700 | 3,700 | - | - | Stock Option (right to buy) | |
| Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Carmine Stengone | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 300,000 | 300,000 | - | - | Stock Option (right to buy) | |
| Peter T. Slover | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| S. Lorrain Daniel | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.02 per share. | 25 Nov 2024 | 1,010 | 168,562 | - | 16.0 | 16,177 | Class A Common Stock |
| Daniel S. Lorrain | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 16.37 per share. | 18 Nov 2024 | 6,091 | 169,671 | - | 16.4 | 99,733 | Class A Common Stock |
| Daniel S. Lorrain | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 17.05 per share. | 18 Nov 2024 | 99 | 169,572 | - | 17.1 | 1,688 | Class A Common Stock |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.01 per share. | 13 Aug 2024 | 12,800 | 12,800 | - | 1.0 | 12,928 | Class A Common Stock |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 12,800 | 161,394 | - | - | Stock Option (right to buy) | |
| Sarah Boyce | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jun 2024 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Daniel S. Lorrain | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 3,700 | 3,700 | - | - | Stock Option (right to buy) | |
| Carmine Stengone | Director, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 285,000 | 285,000 | - | - | Stock Option (right to buy) | |
| Evert B. Schimmelpennink | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | |
| Lori Lyons-Williams | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 29,500 | 29,500 | - | - | Stock Option (right to buy) | |
| Olivia C. Ware | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 3,700 | 3,700 | - | - | Stock Option (right to buy) | |
| Troy A. Ignelzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 6,350 | 6,350 | - | - | Stock Option (right to buy) | |
| Peter T. Slover | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Troy A. Ignelzi | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2024 | 23,150 | 23,150 | - | - | Stock Option (right to buy) |